Human papillomaviruses (HPVs) are a large group (Ͼ100 types) of small DNA viruses that replicate in keratinocytes of squamous epithelia. HPV infections produce hyperproliferative warts that are in most instances benign. A small subset of HPV types, however, form lesions on the skin, and on the oropharyngeal-and anogenital-tract mucosae, that have a significant risk of malignant transformation. The most common cancer attributable to infection with the high-risk HPV types is cancer of the uterine cervix (35). Despite the differences in pathogenesis between virus types, their life cycles are similar (10), beginning with infection of keratinocytes within the basal cell compartment of squamous epithelia. Here the HPV genome is replicated as a low-copy-number (50 to 100 copies per cell) episome in synchrony with the replication of the host cell genome, a process that requires HPV E1 and E2 functions. HPV early proteins E6 and E7 act to expand the population of HPV-infected keratinocytes once they migrate up from the basal layer, by stimulating cell cycle entry and cell survival. The virus then utilizes the host cell's replication machinery, which has been activated in these cells, to amplify the HPV DNA to many thousands of copies per cell during the vegetative stage of the life cycle. Finally, the capsid proteins L1 and L2 are produced, and new progeny are assembled in the most superficial cells prior to their release from the highly differentiated squames.
Human papillomaviruses (HPVs) are a large group (Ͼ100 types) of small DNA viruses that replicate in keratinocytes of squamous epithelia. HPV infections produce hyperproliferative warts that are in most instances benign. A small subset of HPV types, however, form lesions on the skin, and on the oropharyngeal-and anogenital-tract mucosae, that have a significant risk of malignant transformation. The most common cancer attributable to infection with the high-risk HPV types is cancer of the uterine cervix (35) . Despite the differences in pathogenesis between virus types, their life cycles are similar (10) , beginning with infection of keratinocytes within the basal cell compartment of squamous epithelia. Here the HPV genome is replicated as a low-copy-number (50 to 100 copies per cell) episome in synchrony with the replication of the host cell genome, a process that requires HPV E1 and E2 functions. HPV early proteins E6 and E7 act to expand the population of HPV-infected keratinocytes once they migrate up from the basal layer, by stimulating cell cycle entry and cell survival. The virus then utilizes the host cell's replication machinery, which has been activated in these cells, to amplify the HPV DNA to many thousands of copies per cell during the vegetative stage of the life cycle. Finally, the capsid proteins L1 and L2 are produced, and new progeny are assembled in the most superficial cells prior to their release from the highly differentiated squames.
A major protein produced during the HPV life cycle is the E4 protein. It is expressed as an E1^E4 fusion protein from spliced transcripts formed between the N terminus of the E1 open reading frame and almost the complete open reading frame of E4 (21) . The precise function of E4 has not been defined, but loss of expression of the full-length E1^E4 polypeptide has a severe adverse effect on viral genome amplification of HPV type 16 (HPV16), HPV18, and HPV31 following introduction of mutant genomes unable to support E1^E4 expression into keratinocytes and subsequent induction of cellular differentiation (20, 38, 39) . Failure to complete the vegetative stage of the virus life cycle is also the outcome of loss of E1^E4 expression in rabbit papillomas induced by a mutant cottontail rabbit papillomavirus genome (22) . These studies suggest that E4 function is necessary for efficient vegetative replication of the virus, a hypothesis supported by coincidence between onset of viral genome amplification and induction of high-level E4 production in natural papillomavirus infections (23) .
Examination of E4 activity in epithelial cell cultures has revealed diverse biological actions that perhaps imply a multifunctional role for this viral protein in the virus life cycle. These include disruption of ND10 body organization, which might be required for viral DNA replication, either by organization of viral replication centers or by inactivation of a host antiviral response mediated through the nuclear ND10 body (8, 29) . A potent G 2 arrest function is a conserved function of E4 proteins between HPV types with dissimilar tropism, and it is thought that division arrest of infected cells might be necessary to support efficient viral DNA amplification (5, 13, 19) . E4 inclusion bodies found in the cytoplasm of cells of HPV1 skin warts contain the kinase SRPK1, a binding partner of E1^E4 proteins, which is associated with regulating the function of splicing factors (1) . Sequestration of SRPK1 by E4 could be an HPV mechanism to regulate expression of viral late transcripts at the late stages of the replication cycle (1) . Late in the infectious cycle, the E4 protein may also act to diminish the integrity of the keratinocyte by disrupting the keratin cytoskeleton and cornified envelope formation and inducing apoptosis through alteration of mitochondrial function to facilitate egress of the newly formed HPV virions (3, 6, 24, 26) .
Execution of multiple functions might be assisted by conversion of the E4 protein into multiple forms, brought about by a combination of sequential N-terminal proteolysis of the E1^E4 polypeptide (7, 25) and by phosphorylation (9) . Indeed, a study of the interaction between E4 and cell growth revealed an interesting relationship between modification of the HPV1 E4 protein and dysregulation of the cell cycle (13) . During the HPV1 infectious cycle, N-terminal sequences are removed from the full-length 17-kDa E1^E4 polypeptide to produce smaller E4 species of 16, 11, and 10 kDa that progressively replace the full-length protein as the replication cycle proceeds (7, 25) . Expression of the 17-kDa E1^E4 protein in the presence of a protein mimicking the 16-kDa polypeptide in keratinocyte cells inhibits G 2 -to-M transition of the cell cycle, and in a population of cells, prohibition of entry into S phase is also observed (13) . The negative effect on S-phase entry, however, is not apparent in cells expressing the individual forms of E4, although expression of the truncated 16-kDa protein alone was sufficient to block cell division (13) . Further analysis revealed that HPV1 E4 employs two distinct mechanisms to inhibit G 2 -to-M transition: the first, mediated by the combined expression of 17-and 16-kDa proteins, was found to be dependent on maintenance of high levels of the Wee1 kinase to inhibit Cdk1 activity, and the second, mediated by the 16-kDa protein, is associated with insufficient production of cyclin B1 to enable the cells to transverse G 2 to M (13, 14) . Employment of two distinct mechanisms to inhibit cell division suggests that the G 2 arrest function of HPV1 E4 is important in the HPV life cycle. In this study, we investigated how HPV1 E4 inhibits progression of cells into S phase and showed that HPV1 E4 affects a key step in the cellular DNA replication process.
MATERIALS AND METHODS
HPV1 E4 expression plasmids. Construction of plasmids based on pcDNA3.1 that deliver expression of the 17-kDa full-length HPV1 E1^E4 (E4-17K) and an N-terminal truncation (E4-16K) equivalent to the 16-kDa E4 polypeptide was described previously (29) . A set of previously described deletions within the full-length E1^E4 coding sequence (25) were excised and inserted into the BamHI restriction site of pcDNA3.1 (Invitrogen, Carlsbad, CA). The sequence integrity of plasmid inserts was verified by bidirectional DNA sequencing. The substitution-containing proteins E4R45A, E4R47A, and E4R48A are described elsewhere (1) .
Expression of recombinant proteins. HPV1 E4 and Xenopus laevis Cdc6 (His 6 -XeCdc6) proteins were purified from Sf9 insect cells following infection with appropriate recombinant baculoviruses, as previously described (28, 31) . Histidine-tagged human geminin (His 6 -HsGeminin) was expressed in Escherichia coli and purified as described previously (36) . For expression of histidine-tagged HPV1 E4 protein in bacteria, the E1^E4 wild-type and mutant coding sequences were inserted into the BamHI-EcoRI cloning site of the expression vector pRSET-C (Invitrogen) and expressed in E. coli strain BL21(DE3) pLysS (Novagen, Madison, WI). The recombinant protein was purified by immobilized metal affinity chromatography using NiCl 2 -charged HiTrap chelating columns (GE Healthcare Europe GmbH, Munich, Germany). Nonspecifically bound proteins were removed with 4 column volumes (c.v.) of 10% elution buffer (30 mM Tris-Cl [pH 8], 300 mM imidazole, 30 mM NaCl, 0.1 mM phenylmethylsulfonyl fluoride) and 8 c.v. of 20% elution buffer. The E4 proteins were eluted with 2 c.v. of 100% elution buffer and desalted into 20 mM Tris-Cl (pH 8), 50 mM NaCl.
In vitro cellular DNA replication assays. Nuclei and cytosolic extracts were prepared from synchronized NIH 3T3 and HeLa S3 cells and supplemented as described previously (11, 15, 31, 32) . In vitro DNA replication assays were performed as described previously (15, 31) (Fig. 1a) . Briefly, reaction mixtures contained 30 l of cytosolic extracts (250 to 300 g of protein), 10 l of premix buffer (160 mM K-HEPES [pH 7.8], 28 mM MgCl 2, 12 mM ATP, 0.4 mM of GTP, CTP, UTP, dATP, dGTP, and dCTP, 1 M biotin-16-dUTP, 2 mM dithiothreitol, 160 mM creatine phosphate, 20 g phosphocreatine kinase), 1 ϫ 10 5 nuclei, and, where indicated, up to 10 l of recombinant protein(s). His 6 -XeCdc6 protein in 20 mM HEPES (pH 7.4), 150 mM NaCl, 5% glycerol, 1 mM dithiothreitol was added to in vitro replication reaction mixtures at a final concentration of 0.65 M, baculovirus-expressed HPV1 E4 proteins in 10 mM phosphate buffer (pH 7.4), 0.1 mM dithiothreitol at 3 M, bacterially expressed His 6 -E4 proteins in 40 mM Tris-HCl (pH 7.6), 30 mM NaCl, and His 6 -HsGeminin protein in 50 mM sodium phosphate at 4 M. Equal volumes of appropriate buffers were added to control reaction mixtures. All components of the replication reaction mixtures were incubated together on ice for 15 min prior to the addition of S-phase cytosol and incubation for 3 h at 37°C. For analysis of in vitro DNA synthesis reactions by confocal microscopy, reactions were stopped by diluting with 500 l of phosphate-buffered saline (PBS), and nuclei were fixed for 5 min in 4% paraformaldehyde. After fixation, nuclei were spun through a 30% sucrose-PBS cushion onto poly-L-lysine-coated coverslips. All subsequent washing and staining steps were carried out in PBS, 0.2% Triton X-100, 0.04% sodium dodecyl sulfate. Coverslips were washed, stained for incorporated biotin-16-dUTP with fluorescein-linked streptavidin (1:100 dilution; Amersham) and for DNA with propidium iodide-RNase A (both at 50 ng/ml), washed again, and mounted in Vectashield (Vector Laboratories, Ltd., Peterborough, United Kingdom). Confocal fluorescence microscopy of random fields of nuclei was performed on a Leica TCS DMRE confocal microscope, and the numbers of nuclei incorporating biotin-16-dUTP in vitro and nonreplicating nuclei were counted. Routinely, 800 to 1,000 nuclei were scored blind by a single individual for each reaction and quantitated as percentages of the total number of nuclei that synthesized DNA in vitro. More than one preparation of nuclei was assayed, in triplicate, for each set of experiments, and analysis was performed by two individuals. Statistical analysis of data from multiple independent experiments was performed by singlefactor analysis of variance.
Chromatin-binding assay. In vitro DNA replication assays were set up as described above. After 3 h incubation, nuclei were pelleted by low-speed (1,300 ϫ g) centrifugation and used in chromatin-binding reactions performed as described previously (12) . Samples were immunoblotted with antibodies against Mcm2 (BD Biosciences; 610701), Mcm7 (Neomarkers; Lab Vision, Suffolk, United Kingdom; MS-862-P), Cdc6 (Santa Cruz, Santa Cruz, CA; 9964), HPV1 E4 (MAb 4.37) (7) and histone H1 (Santa Cruz; 10806). Analysis of protein bands using densitometry was determined using ImageJ (http://rsb.info.nih.gov /ij). Chromatin-binding reactions were repeated at least twice in separate in vitro DNA replication assays.
Cell transfection and cell cycle analysis. Cos-1 cells were transfected with the appropriate combinations of HPV1 E4 expression plasmids, or the pcDNA3.1 empty vector as a control plasmid, as described previously (13) . At 48 h posttransfection, the cells were incubated with 5-bromodeoxyuridine (BrdU) at a final concentration of 33 M for 2 h. Cells were then fixed, incubated with an anti-BrdU antibody conjugated to fluorescein isothiocyanate, labeled with propidium iodide, and analyzed by dual-parameter flow cytometry as described previously (13) . Statistical analysis of data derived from multiple independent experiments was performed by analysis of variance. Expression of E4 proteins was confirmed by immunoblot analysis using monoclonal antibody MAb 4.37.
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FIG. 1. HPV1 E4 inhibits initiation of cellular DNA synthesis in an in vitro replication assay. (a) Cell-free cellular DNA replication system. Nuclei (N) prepared from G 1 -phase NIH 3T3 fibroblasts, synchronized by release from quiescence (G 0 ), initiate a single round of semiconservative DNA replication in cytosolic extracts (SC) from S-phase HeLa cells following incubation in buffer A (BA) (which supports elongation), nucleotides (dNTPs, NTPs), and an ATP regeneration system (CP, CK). Nuclei were stained with propidium iodide (red) to reveal DNA and with fluorescein-streptavidin (green) to detect biotin-16-dUTP incorporation resulting from in vitro DNA synthesis. (b) Coomassie-stained sodium dodecyl sulfate-polyacrylamide gel of baculovirus recombinant HPV1 E4 proteins. Lane 1, molecular mass standards (12.3, 17.2, 30, 42.7, 66 , and 76 kDa); lanes 2 and 3, purified HPV1 E4 proteins WT38 and WT43 containing variable levels of full-length E1^E4 (17-kDa) and processed (16-and 11-kDa) species. (c) NIH 3T3 G 1 nuclei were incubated in cytosolic extracts from S-phase HeLa cells, which induces initiation in competent nuclei, or in elongation buffer (buffer A), which supports elongation DNA synthesis only in nuclei that are already in S phase. Addition of E4 (but not ⌬E4) and Cdc6 to coincubation mixtures inhibits DNA synthesis at a level comparable to that achieved with geminin. Results are expressed as the percentage of nuclei replicating (mean Ϯ standard deviation), and asterisks indicate a significance of Ͼ99.99% in the decrease of replicating nuclei compared to control replication assays. (d) Addition of E4 and Cdc6 to coincubation mixtures of NIH 3T3 S-phase nuclei and HeLa S-phase cytosol had no effect on replication potential. Similarly, addition of geminin did not affect ongoing DNA synthesis. Data were analyzed as described for panel c.
RESULTS
HPV1 E4 inhibits cellular DNA replication in vitro. We sought to establish whether the negative effect of HPV1 E4 upon S-phase entry reflected an interaction between the viral protein and the process of cellular DNA synthesis itself. To do this, we took advantage of an established cell-free DNA replication system that supports efficient cellular DNA synthesis under somatic cell cycle control (31) (Fig. 1a) . Previous characterization of this system had revealed that nuclei prepared from quiescent (G 0 ) NIH 3T3 fibroblasts cannot initiate DNA synthesis in S-phase cytosolic extracts of HeLa cells, while G 1 nuclei become competent to initiate DNA replication in the S-phase extracts when prepared 16 to 18 h after release from G 0 (31) .
NIH 3T3 G 1 nuclei were combined with HeLa S-phase cytosol and incubated for 3 h in the presence of an ATP generation system and nucleotides (nucleoside triphosphates [NTPs] and deoxynucleoside triphosphates [dNTPs]), including biotinlabeled dUTP as a marker to enable detection of DNA synthesis by confocal microscopy (Fig. 1a) . We observed that 19.3% of G 1 nuclei were capable of DNA synthesis in the presence of S-phase cytosol, in comparison to only 2.2% following incubation of the G 1 nuclei in a physiological buffer (buffer A) that supports elongation but not initiation of DNA replication (Fig. 1c) . The small proportion of replication-competent nuclei observed in buffer A represent contaminating S-phase nuclei present in the G 1 nuclear preparation that continue DNA synthesis at replication forks established in vivo prior to their isolation (31) . Thus, 17.1% of G 1 nuclei undergo true replication initiation in the presence of S-phase cytosol. To confirm that our preparations of G 1 nuclei and S-phase cytosol respond to exogenous factors, we first tested the response to recombinant preparations of the replication-licensing factor (RLF) Cdc6 (His 6 -XeCdc6) and geminin (His 6 -HsGeminin), a known cellular repressor of replication licensing (18) .
The percentage of replicating nuclei increased from 19.3% to 23% in reaction mixtures containing His 6 -XeCdc6 (Fig. 1c) . Since Cdc6 is known to be rate limiting for replication competence after release from G 0 (31), the small but consistent increase in replicating nuclei in the presence of His 6 -XeCdc6 indicates that a low number of G 1 nuclei are responsive to this RLF. In contrast, in the presence of His 6 -HsGeminin there was a marked and significant decrease (7.2%) in the percentage of replication-competent nuclei (Fig. 1c) .
To investigate if HPV1 E4 might interfere with cellular DNA synthesis, the viral protein was expressed in Sf9 insect cells using a recombinant baculovirus and the purified protein (Fig. 1b, WT38 ) titrated into in vitro replication reaction mixtures (Fig. 1c) . While we observed no significant effect of E4 on the percentage of nuclei synthesizing DNA in coincubations of G 1 nuclei and S-phase cytosol (19.7%), when E4 was added to reaction mixtures that also contained exogenous Cdc6 (His 6 -XeCdc6), the percentage of replicating nuclei decreased significantly from 23% to 10.6%, indicating that 54% of the replication-competent nuclei failed to initiate DNA synthesis (Fig.  1c) . Notably, the scale of E4-induced replication inhibition was comparable to the inhibitory effect (67%) of His 6 -HsGeminin (Fig. 1c) .
The E4 protein added to the in vitro replication assays contained the full-length E1^E4 protein (17 kDa) plus small quantities of truncated polypeptides (16, 11 , and 10 kDa) (Fig. 1b,  WT38) . Interestingly, addition of recombinant E4 protein that contained the truncated proteins but no full-length E1^E4 polypeptide (Fig. 1b, WT43 ) to the cell-free replication assay did not inhibit DNA synthesis in the G 1 nuclei in either the absence (data not shown) or presence (Fig. 1c, ⌬E4 ) of exogenous Cdc6. This observation suggests that E4-induced inhibition of cellular DNA synthesis in vitro requires the presence of the full-length E1^E4 protein.
To validate the specificity of our findings, identical replication reactions to those described above but using a separate preparation of baculovirus-expressed E4 protein containing a similar profile of E4 species to WT38 and G 1 nuclei prepared from human WI38 diploid fibroblasts achieved a similar level of replication inhibition (55%; data not shown).
HPV1 E4 does not arrest ongoing cellular DNA synthesis in vitro. Unlike G 1 nuclei, nuclei isolated from cells in the S phase of the cell cycle contain active replication forks and are thus competent for DNA synthesis in the absence of cytosolic S-phase extracts (31) . Addition of geminin, an inhibitor of origin licensing, to in vitro replication reaction mixtures containing NIH 3T3 S-phase nuclei as the source of the template failed to affect ongoing DNA synthesis (Fig. 1d) , consistent with previous reports (18, 33, 40) . Significantly, cellular DNA elongation was also not affected by the addition of recombinant E4 protein (WT38) to S-phase nuclei, in either the absence or presence of His 6 -XeCdc6 (Fig. 1d) . The data from the in vitro replication assay (Fig. 1) indicate that in the presence of exogenous Cdc6, HPV1 E4 inhibits initiation of DNA synthesis but fails to arrest ongoing DNA synthesis.
HPV1 E4 blocks recruitment of replication licensing proteins onto chromatin in vitro. Initiation of cellular DNA replication is achieved by the ordered assembly of prereplicative complexes (pre-RCs) at origins of replication (34) . During late mitosis (M) and early G 1 phase, the RLFs Cdc6 and Cdt1, by interacting with the origin recognition complex, load the putative DNA replicative helicase Mcm2-7 onto chromatin to form pre-RCs. In the subsequent S phase, DNA replication is initiated at these "licensed" origins by the concerted action of cyclin-dependent kinases and Cdc7-Dbf4. To investigate whether HPV1 E4 might inhibit replication initiation by blocking assembly of pre-RCs onto chromatin, we resolved chromatin-bound protein fractions prepared from G 1 -and S-phase nuclei subjected to in vitro replication reactions by gel electrophoresis and probed for the RLFs Cdc6, Mcm2, and Mcm7 (Fig. 2) . Histone H1 levels were used as a loading control. Chromatin prepared from G 1 nuclei incubated with S-phase cytosol showed a twofold increase in the binding of endogenous Cdc6 and MCM factors compared to the elongation control reaction (buffer A) (Fig. 2a) . Addition of recombinant Cdc6 to replication reaction mixtures led to a 1.5-fold increase in the total amount of chromatin-bound Cdc6 and further increased levels of chromatin-bound MCMs (Fig. 2a) , correlating with the observed small increase in the percentage of replication-competent nuclei (Fig. 1c) . In contrast, geminin inhibited origin licensing by blocking loading of Mcm2 onto chromatin (Fig. 2a) , indicating that increased levels of chromatin-bound RLFs in nuclei subjected to the replication assay (Fig. 2a) . Notably, the reduced levels of chromatin-bound MCM proteins were close to base levels measured in G 1 nuclei incubated with buffer A (Fig. 2a) . The reduction of chromatin-bound MCM proteins by the HPV1 protein correlated with its ability to inhibit replication, as Mcm2 and Mcm7 levels were not affected by addition of E4 in the absence of exogenous Cdc6 or by the addition of E4 protein lacking full-length E1^E4 protein (⌬E4) to reaction mixtures containing His 6 -XeCdc6 (Fig. 2a) . There was no evidence that E4 became bound to chromatin, in either the presence or absence of exogenous Cdc6 (see Fig. 4b ). Chromatin-binding studies on S-phase nuclei subjected to replication elongation assays showed that neither geminin nor E4 added together with His 6 -XeCdc6 affected the chromatinbinding status of Mcm2 and Mcm7 (Fig. 2b) .
Together, the in vitro replication and chromatin-binding data indicate that inhibition of initiation of cellular DNA synthesis by HPV1 E4 in the presence of His 6 -XeCdc6 correlates with reduced MCM loading onto chromatin.
Repression of S-phase entry by HPV1 E4 in epithelial cells is dependent on an arginine-rich motif in the E1^E4 protein.
To determine whether there is a relationship between the negative effect of HPV1 E4 on cell proliferation (13) and E4's ability to inhibit cellular DNA replication in vitro, we first identified the HPV1 E1^E4 sequences required for suppression of S-phase entry in epithelial cells. Since the negative effect of HPV1 E1^E4 on S-phase entry was dependent on the presence of a truncated 16-kDa E4 protein (13) , HPV1 E1^E4 (E4-17K) expression plasmids containing small deletions that cover the majority of the E1^E4 sequence were individually cotransfected with the plasmid expressing the truncated pro- tein (E4-16K) into Cos-1 epithelial cells, and cellular DNA synthesis was monitored by BrdU incorporation. In keeping with our previous findings (13) , transient expression of the full-length E1^E4 protein together with E4-16K reduced Sphase BrdU incorporation nearly twofold, in comparison to cells expressing the individual proteins or control cells (Table  1) . Of the E1^E4 deletion plasmids tested, only one, containing a deletion of residues 44 to 48 (GRPRR), did not inhibit S-phase entry following cotransfection with E4-16K ( Table 1) . The G 2 arrest function of this mutant E1^E4 protein, however, remained intact (data not shown).
The contribution of individual amino acids within the 44 GRPRR 48 sequence to E1^E4 function was examined by replacing the arginine residues at positions 45, 47, and 48 with alanine residues (E4R45A, E4R47A, and E4R48A). Following cotransfection of these mutant E1^E4 plasmids with the E4-16K expression plasmid into Cos-1 cells, BrdU incorporation revealed that inhibition of entry into S phase was sensitive to alanine substitution of Arg45 but not mutation of Arg47 or Arg48 (Fig. 3a) . Loss of inhibitory action was not due to any change in the stability of the E4R45A E1^E4 protein in epithelial cells (Fig. 3b) , and all three mutants promoted G 2 arrest to levels comparable to those obtained with E4-17/16K-expressing cells (data not shown).
The arginine-rich motif in E1^E4 is necessary for inhibition of cellular DNA synthesis initiation in vitro. Next, we wanted to determine whether the 44 GRPRR 48 sequence E1^E4 was also involved in inhibition of cellular origin licensing in the in vitro replication assay. In this instance, the recombinant HPV1 E4 proteins were expressed in and purified from bacteria. To verify that a bacterial form of the E4 protein has an inhibitory function, the wild-type protein was titrated into the in vitro replication reaction mixtures. Consistent with the data obtained by using baculovirus recombinant E4 protein, we observed no significant effect of E4 on the percentage of nuclei synthesizing DNA following addition of the bacterial E4 protein to coincubation mixtures of NIH 3T3 G 1 nuclei and HeLa S-phase cytosol (24%; data not shown). However, when E4 was added to reaction mixtures that also contained exogenous Cdc6 (His 6 -XeCdc6), the percentage of replicating nuclei decreased significantly, from 29% to 13.8%, indicating that in the presence of a bacterial HPV1 E4 protein nearly 53% of the replication-competent nuclei failed to initiate DNA synthesis (Fig. 4a) . Inhibition of cellular replication initiation was, however, abrogated upon the addition of the E4 protein containing a deletion of 44 GRPRR 48 to the in vitro reaction mixtures containing His 6 -XeCdc6 (23.2% [Fig. 4a]) , and alanine substitution of arginine 45 (E4R45A) within this motif was sufficient to relieve the inhibitory effect of the HPV protein (26.5% [Fig. 4a]) .
Our analysis of pre-RC assembly in the in vitro replication assay had indicated that HPV1 E4 protein inhibited loading of MCM onto chromatin (Fig. 2) . Therefore, we investigated whether failure to inhibit replication initiation by the mutant E1^E4 proteins correlated with efficient assembly of pre-RCs onto chromatin. Chromatin-bound protein fractions prepared from G 1 -and S-phase nuclei subjected to in vitro replication reactions were probed for the RLFs Cdc6, Mcm2, and Mcm7 on November 1, 2017 by guest http://jvi.asm.org/ (Fig. 4b) . Chromatin prepared from G 1 nuclei incubated with S-phase cytosol in the presence of His 6 -XeCdc6 and the wildtype protein derived from bacteria showed 51% and 41% decreases in chromatin-bound Mcm2 and Mcm7, respectively, compared to the levels of these proteins in the reaction mixture containing His 6 -XeCdc6 alone (Fig. 4b) . The reductions in the levels of chromatin-bound MCM proteins in the presence of the bacterial preparation of E4 were similar to the decrease observed with the baculovirus recombinant E4 protein (Fig. 2) . However, in the presence of the mutant E1^E4 proteins E4⌬44-48 and E4R45A, both Mcm2 and Mcm7 were efficiently recruited to chromatin (Fig. 4b) .
Together, our data suggest that HPV1 E4 inhibits initiation of cellular DNA replication in vitro by blocking MCM loading onto chromatin and that this is dependent on an arginine-rich motif within the full-length form of the viral protein. Mcm2 and Mcm7 onto chromatin. The functional effect of E4 mimics the cellular repressor of replication licensing geminin (18) , but while geminin interacts with the RLF Cdt1 to inhibit assembly of MCMs into pre-RCs, the mechanism by which E4 blocks MCM loading appears to be different from that of the cellular repressor. Unlike geminin, inhibition of licensing in vitro by E4 requires addition of an exogenous supply of soluble Cdc6. The requirement for exogenous Cdc6 for E4-mediated inhibition of DNA replication may be explained by the differential regulation of Cdc6 in normal proliferating cells, where Cdc6 is found in both the soluble and chromatin-bound fractions (30) , and during the G 0 -S transition, where Cdc6 is synthesized de novo and immediately recruited to replication origins (12) . In the in vitro replication assay used in this study, NIH 3T3 G 1 nuclei are prepared during release from densitydependent growth arrest (G 0 ) and therefore contain only chromatin-bound Cdc6 (31) . How HPV1 E4 and the soluble form of the licensing factor Cdc6 function together to inhibit replication is not yet understood, but they are sufficient to block MCM recruitment to origins even in the presence of chromatin-bound Cdc6. One possibility is that E4 is able to complex with MCM factors in a soluble-Cdc6-dependent manner. There is evidence of an association between a glutathione S-transferase-HPV1 E1^E4 fusion protein and an epitopetagged form of Mcm7 expressed in cell lysates containing soluble Cdc6 (I. Bell and Sally Roberts, unpublished data). Association between E1^E4 and this MCM factor, however, might not be a complete description of the mechanism of E4-mediated replication inhibition, since ⌬E4, the form of HPV1 E4 defective in inhibiting cellular DNA synthesis, can form an association with Mcm7 (I. Ashmole and S. Roberts, unpublished data). It is feasible that further modification (for example, a phosphorylation event) is necessary to achieve an "active" inhibitory complex, and this might be dependent on N-terminal sequences specific to the full-length E1^E4 polypeptide. Whatever the underlying mechanism, inhibition of initiation of cellular DNA replication in vitro and suppression of entry of epithelial cells into S phase are functions that are both dependent on arginine 45 in the HPV1 E1^E4 polypeptide, suggesting that these two functions are linked and hence that E4 can block cellular DNA synthesis in the presence of endogenous soluble Cdc6.
DISCUSSION
Our studies have shown that E4-induced inhibition of in vitro replication initiation is dependent on a full-length E1^E4 molecule. It is possible that the smaller forms of E4 that exist in the purified preparations of HPV1 E4 protein used in this study may contribute to this E1^E4 function. Indeed, HPV1 E4 expression studies show that coexpression of full-length and truncated forms of HPV1 E4 act to repress cell proliferation, while expression of the full-length form alone do not (13) . Complex formation between the different E4 polypeptides (14) might be one explanation: the complex might either inhibit S-phase entry directly or, upon formation, deplete free fulllength protein to a level that it is then active with regard to blocking cell proliferation. This latter explanation might well explain why there is no block in cell proliferation in cells expressing the E1^E4 protein alone even though a small amount of the truncated E4 species does accumulate in these cells.
We do not know at this stage of our investigations whether this novel HPV1 E4 function is conserved between the different phylogenetic types. Arginine 45 lies in a region of HPV1 E4 that is rich in basic amino acids, and indeed, similar (but not identical) regions are to be found in E4 proteins of types with a tropism dissimilar to that of HPV1, such as HPV16 and -18, which have a preference for epithelia of the oral and anogenital tracts (1) . The basic region of HPV16 E4 forms part of the G 2 arrest domain (5), but in HPV1, E4 is not a required element of the G 2 arrest function, nor do these regions contribute to the interaction with the keratin cytoskeleton (25, 27 ). An association between HPV1 E4 and the SR protein kinase SRPK1 is dependent on arginine 45 (1), although other sequences required to maintain this interaction do not contribute to inhibition of cell proliferation, suggesting that this E4 binding partner is unlikely to be involved in the underlying mechanism of replication inhibition by HPV1 E4. Therefore, arginine 45 either mediates an association to a novel E4-binding protein or dictates a specific cellular localization necessary for replication inhibition. Host cell DNA synthesis is blocked during the Epstein-Barr virus (EBV) lytic infection cycle, during which there is highlevel amplification of the EBV genome (17) . EBV inactivates MCM helicase function by phosphorylation of MCM proteins, and this might be sufficient to block cellular DNA synthesis in lytic infected cells (16) . Infection by another DNA virus, cytomegalovirus, also abrogates cellular replication licensing by inhibiting chromatin loading of MCM proteins (2, 37) . Even though the underlying mechanisms of repression of cellular DNA replication by EBV and CMV were not identified, taken together with our study, this observation implies that unrelated DNA viruses may have evolved similar strategies to selectively inhibit host cell DNA synthesis. This function could prove advantageous to viruses that depend on the host cell for the supply of essential replication enzymes and nucleotides for viral DNA synthesis. Papillomaviruses have three phases of replication: establishment and maintenance of the genome in basal cells are followed by vegetative genome amplification in cells that have migrated up from the basal layer and differentiated (10) . Because keratinocyte differentiation normally correlates with exit from the cell cycle, the virus induces S-phase gene activity in these cells, and eventually they initiate vegetative viral genome replication, whereby the viral genome is amplified to high copy number (4) . Notably, the switch to genome amplification is associated with induction of E4 protein (23) . Furthermore, more recently, it was shown that this switch also correlates with suppression of cellular DNA synthesis in replication-activated HPV16-containing keratinocytes (20) . We therefore hypothesize that in these cells, E4 acts to preserve the supply of essential host replication factors by inhibiting licensing of cellular origins of replication and thus repress competing cellular DNA synthesis. Combined with action on G 2 -to-M transition of the cell cycle (5, 13, 19) , E4 could be a key player in ensuring successful replication of the virus. Indeed, loss of expression of the full-length E1^E4 protein is associated with an abrogation of efficient vegetative genome replication in systems that recapitulate the productive replication life cycles of HPV16, -18, and -31 and cottontail papillomavirus (20, 22, 38, 39) .
Viral factors such as E4 could provide powerful molecular tools that can be utilized to dissect the molecular mechanisms VOL. 82, 2008 HPV E4 INHIBITS CELLULAR DNA SYNTHESIS 9063 regulating initiation of eukaryotic DNA replication. Furthermore, because the origin licensing machinery has been proposed as a novel attractive target for anticancer therapy, the design of E4-based mimetic compounds could provide novel nongenotoxic agents.
